Answers are grounded in this paper and cite their sources.
// Hae Ryung Chang 1, 2, * , Seungyoon Nam 1, 3, * , Jinhyuk Lee 4, 5, * , Jin-Hee Kim 6, * , Hae Rim Jung 1 , Hee Seo Park 7 , Sungjin Park 1, 3 , Young Zoo Ahn 1 , Iksoo Huh 8 , Curt Balch 9 , Ja-Lok Ku 10 , Garth Powis 11 , Taesung Park 8 , Jin-Hyun Jeong 6 , Yon Hui Kim 1, 12 1 New Experimental Therapeutics Branch, National Cancer Center of Korea, Goyang-si, Republic of Korea 2 Research Institute of Women’s Health, Sookmyung Women’s University, Seoul, Republic of Korea 3 College of Medicine, Gachon University, Incheon, Republic of Korea 4 Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea 5 Department of Nanobiotechnology and Bioinformatics, Korea University of Science and Technology, Daejeon, Republic of Korea 6 College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea 7 Animal Sciences Branch, National Cancer Center of Korea, Goyang-si, Republic of Korea 8 Department of Statistics, Seoul National University, Seoul, Republic of Korea 9 Bioscience Advising, Ypsilanti, MI, USA 10 Korean Cell Line Bank, Seoul National University, Seoul, Republic of Korea 11 Cancer Center, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA 12 Discovery Biology, CrystalGenomics Inc., Seongnam-si, Republic of Korea * These authors have contributed equally to this work Correspondence to: Yon Hui Kim, email: yhkim@cgxinc.com Jin-Hyun Jeong, email: organicjeong@yonsei.ac.kr Taesung Park, email: tspark@stats.snu.ac.kr Keywords: gastric cancer, RHOA, G-protein, biomarker, therapeutic target Received: July 11, 2016 Accepted: October 17, 2016 Published: October 28, 2016 ABSTRACT Gastric cancer (GC) is a highly heterogeneous disease, in dire need of specific, biomarker-driven cancer therapies. While the accumulation of cancer “Big Data” has propelled the search for novel molecular targets for GC, its specific subpathway and cellular functions vary from patient to patient. In particular, mutations in the small GTPase gene RHOA have been identified in recent genome-wide sequencing of GC tumors. Moreover, protein overexpression of RHOA was reported in Chinese populations, while RHOA mutations were found in Caucasian GC tumors. To develop evidence-based precision medicine for heterogeneous cancers, we established a systematic approach to integrate transcriptomic and genomic data. Predicted signaling subpathways were then laboratory-validated both in vitro and in vivo , resulting in the identification of new candidate therapeutic targets. Here, we show: i) differences in RHOA expression patterns, and its pathway activity, between Asian and Caucasian GC tumors; ii) in vitro and in vivo perturbed RHOA expression inhibits GC cell growth in high RHOA-expressing cell lines; iii) inverse correlation between RHOA and RHOB expression; and iv) an innovative small molecule design strategy for RHOA inhibitors. In summary, RHOA, and its oncogenic signaling pathway, represent a strong biomarker-driven therapeutic target for Asian GC. This comprehensive strategy represents a promising approach for the development of “hit” compounds.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: